# Regorafenib

## Stivarga 40mg (28#/Bot)

##### 臨採

| TAH Drug Code      | [**OSTV**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OSTV)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Colorectal cancer: Treatment of patients with metastatic colorectal cancer (mCRC) who have previously received the following therapies, including fluoropyrimidine-, oxaliplatin-, irinotecan-based chemotherapy, and anti-vascular endothelial growth factor (anti-VEGF) therapy; If KRAS is a wild type, the patient needs to have received anti-epidermal growth factor receptor (anti-EGFR) therapy. Gastrointestinal stromal tumors: Treatment of locally advanced, unresectable or metastatic gastrointestinal stromal tumors in patients who have previously received imatinib mesylate and sunitinib malate. Hepatocellular carcinoma: Treatment of hepatocellular carcinoma (HCC) patients who have received sorafenib treatment. |
| Dosing             | 160 mg (four 40 mg tablets) taken orally once daily for the first 21 days of each 28-day cycle. Continue treatment until disease progression or unacceptable toxicity.Take Stivarga at the same time each day. Swallow tablet whole with a low-fat breakfast that contains less than 30% fat. Examples of a low-fat breakfast include 2 slices of white toast with 1 tablespoon of low-fat margarine and 1 tablespoon of jelly, and 8 ounces of skim milk (319 calories and 8.2 g fat); or 1 cup of cereal, 8 ounces of skim milk, 1 slice of toast with jam, apple juice, and 1 cup of coffee or tea (520 calories and 2 g fat).                                                                                                          |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Contraindications  | Hypersensitivity to regorafenib, any component of the formulation, or sorafenib.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Adverse Effects    | Hypertension, Fatigue, dysphonia, pain, fever, headache, Palmar-plantar erythrodysesthesia, rash, alopecia, Hypocalcemia, hypophosphatemia, hyponatremia, hypokalemia, hypothyroidism, Appetite decreased, lipase increased, diarrhea, mucositis, weight loss, amylase increased, nausea, vomiting, Anemia, lymphopenia, thrombocytopenia, INR increased, hemorrhage, neutropenia, AST increased, ALT increased, hyperbilirubinemia, Stiffness, Proteinuria, Infection.                                                                                                                                                                                                                                                                    |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

